Literature DB >> 3263911

Human immunodeficiency virus-related lymphocytic alveolitis.

J M Guillon1, B Autran, M Denis, P Fouret, F Plata, C M Mayaud, G M Akoun.   

Abstract

We observed 276 HIV-infected patients to determine the frequency, degree, and clinical presentation of the lymphocytic alveolitis in different stages of HIV disease, and also to identify the lymphocyte subsets involved. In 154 patients with proved lung infections or tumors (group A), bronchoalveolar lavage fluid showed lymphocytosis in 78 percent of cases. In 122 subjects (31 AIDS and 91 HIV-infected non-AIDS patients) without evidence of lung tumor or infection (group B), lymphocytic alveolitis was seen in 72 percent of cases. In 61 of 88 (69 percent) group B lymphocytic patients, we observed respiratory symptoms or diffuse interstitial opacities; however, we also observed such alveolitis in 27 of 46 (59 percent) group B patients free of respiratory symptoms and abnormality of chest x-ray film. This alveolitis was seen not only in AIDS or ARC patients but also at earlier stages of HIV infection. T-lymphocyte analysis showed a large majority (40 to 93 percent) of CD8 positive lymphocytes in the 37 patients tested. A dual fluorescence analysis revealed, in 18 subjects, that those cells were phenotypically cytotoxic (CD8 + D44 +). These findings suggest that, regardless of HIV-infection stages and of opportunistic lung infections, a CD8-positive T-lymphocyte alveolitis may be present in HIV-infected patients and could be responsible for cough, dyspnea, interstitial pneumonitis, and abnormalities of pulmonary function tests.

Entities:  

Mesh:

Year:  1988        PMID: 3263911     DOI: 10.1378/chest.94.6.1264

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  25 in total

1.  CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual.

Authors:  C E Mackewicz; H W Ortega; J A Levy
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

2.  Concomitant sarcoidosis and HIV infection.

Authors:  K S Gowda; I Mayers; S D Shafran
Journal:  CMAJ       Date:  1990-01-15       Impact factor: 8.262

Review 3.  AIDS and the lung: update 1995. 4. Role of the human immunodeficiency virus within the lung.

Authors:  J R Clarke; D S Robinson; R J Coker; R F Miller; D M Mitchell
Journal:  Thorax       Date:  1995-05       Impact factor: 9.139

Review 4.  Immunophenotyping of bronchoalveolar lavage lymphocytes.

Authors:  R J Harbeck
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

Review 5.  The complexity of HIV persistence and pathogenesis in the lung under antiretroviral therapy: challenges beyond AIDS.

Authors:  Sharilyn Almodovar
Journal:  Viral Immunol       Date:  2014-05-05       Impact factor: 2.257

6.  Evaluation of human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T-lymphocyte responses utilizing B-lymphoblastoid cell lines transduced with the CD4 gene and infected with HIV-1.

Authors:  M J McElrath; M Rabin; M Hoffman; S Klucking; J V Garcia; P D Greenberg
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

7.  Alveolar macrophages from subjects infected with HIV-1 express macrophage inflammatory protein-1 alpha (MIP-1 alpha): contribution to the CD8+ alveolitis.

Authors:  M Denis; E Ghadirian
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

8.  Highly active antiretroviral therapy reduces pulmonary IL-8 in HIV-positive women smokers.

Authors:  Gregory H Taylor; Adrienne A Williams; Alfredo Garzino-Demo
Journal:  Pathog Dis       Date:  2015-12-09       Impact factor: 3.166

9.  Reduced carbon monoxide transfer factor (TLCO) in human immunodeficiency virus type I (HIV-I) infection as a predictor for faster progression to AIDS.

Authors:  R B Nieman; J Fleming; R J Coker; J R Harris; D M Mitchell
Journal:  Thorax       Date:  1993-05       Impact factor: 9.139

10.  Primary HIV-I infection associated with pneumonitis.

Authors:  E L Ong; B K Mandal
Journal:  Postgrad Med J       Date:  1991-06       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.